Year of birth: 1946

BIOGRAPHY

Harry Bartelink was Head of the department of radiotherapy at the NKI (The Netherlands Cancer Institute) in Amsterdam. He was the study coordinator of the EORTC 22846 trial to demonstrate in anal cancers the superiority of a combination of Mitomycine-C and 5FU and radiotherapy versus radiotherapy alone.

He constituted one of the foremost radiotherapy teams in Europe with a solid group of physicists (under the direction of Marcel van Herk and Ben Minjheer) who brought major improvements in high precision novel techniques and quality assurance.

Harry did the analysis of the boost versus no boost trial in breast cancers (with the EORTC statistician Laurence Collette) and actively participated to nearly all EORTC and ESTRO ventures